← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #134 OF 1,000 MOST-CITED

SOPs not followed / documented

FDA cited this observation 173 times across 168 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs173
BY FISCAL YEAR
FY202612
FY202523
FY202411
FY202316
FY202220
FY202115
FY20207
FY201923
FY201829
FY201717

How FDA worded it — real examples

Written production and process control procedures are not followed in the execution of production and process control functions.

Viatris Pharmaceuticals LLC · Vega Baja, Puerto Rico · Drugs · 2026-05-18

Written production and process control procedures are not followed in the execution of production and process control functions.

Sciegen Pharmaceuticals Inc · Hauppauge, New York · Drugs · 2026-05-15

Written production and process control procedures are not followed in the execution of production and process control functions.

Micro Measurement Laboratories, Inc. · Wheeling, Illinois · Drugs · 2026-04-28

Written production and process control procedures are not followed in the execution of production and process control functions.

Ajanta Pharma Ltd. · Paithan · Drugs · 2026-04-21

Written production and process control procedures are not followed in the execution of production and process control functions.

Catalent Massachusetts, LLC · Chelsea, Massachusetts · Drugs · 2026-04-07

Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.

Dr. J Skinclinic, Inc · Cerritos, California · Drugs · 2026-03-23

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →